USRE41028EExpiredUtility

Treating eye disorders intestinal trefoil proteins

70
Assignee: GEN HOSPITAL CORPPriority: Apr 12, 1996Filed: Jun 9, 2003Granted: Dec 1, 2009
Est. expiryApr 12, 2016(expired)· nominal 20-yr term from priority
Inventors:Daniel Podolsky
A61K 38/00C07K 14/575
70
PatentIndex Score
1
Cited by
175
References
21
Claims

Abstract

Intestinal trefoil factors and nucleic acids encoding intestinal trefoil factors are disclosed. The intestinal trefoil factors disclosed are resistant to destruction in the digestive tract and can be used for the treatment of peptic ulcer diseases, inflammatory bowel diseases, eye disorders and other insults.

Claims

exact text as granted — not AI-modified
1. A method for the treatment of a disruption of the corneal epithelium in a pateint, said method comprising administering to the eye of said patient a trefoil protein selected from the group consisting of intestinal trefoil factor (ITF), spasmolytic peptide (SP), pS2, and biologically active fragments thereof. 
     
     
       2. The method of  claim 1 , wherein said trefoil protein is a human trefoil protein. 
     
     
       3. The method of  claim 2 , wherein said trefoil protein is intestinal trefoil factor (ITF). 
     
     
       4. The method of  claim 2 , wherein said trefoil protein is spasmolytic peptide (SP). 
     
     
       5. The method of  claim 2 , wherein said trefoil protein is pS2. 
     
     
       6. The method of  claim 1 , wherein said disorder is a corneal ulcer, or is caused by a traumatic physical injury, eye surgery, a chemical exposure, or an ultraviolet light exposure. 
     
     
       7. The method of  claim 1 , wherein administration is topical. 
     
     
       8. A method for the treatment of a disruption of the corneal epithelium in a patient, said method comprising administering to the eye of said patient a trefoil protein comprising a region having at least  90 %  sequence identity to residues  33 - 70  of the polypeptide set forth in SEQ ID NO:  2 , or at least  90   %  sequence identity to residues  25 - 62  of the polypeptide set forth in SEQ ID NO:  4 , wherein said trefoil protein has the ability to enhance corneal epithelial wound healing.    
     
     
       9. The method of  claim 8 , wherein said trefoil protein is the polypeptide set forth in SEQ ID NO:  2  or a biologically active fragment thereof comprising residues  33 - 70  of said polypeptide set forth in SEQ ID NO:  2 , wherein said trefoil protein has the ability to enhance corneal epithelial wound healing.  
     
     
       10. The method of  claim 8 , wherein said trefoil protein is the polypeptide set forth in SEQ ID NO:  4  or a biologically active fragment thereof comprising residues  25 - 62  of said polypeptide set forth in SEQ ID NO:  4 , wherein said trefoil protein has the ability to enhance corneal epithelial wound healing.  
     
     
       11. The method of  claim 8 , wherein said trefoil protein comprises a region having at least  90 %  sequence identity to residues  33 - 70  of the polypeptide set forth in SEQ ID NO:  2 , wherein said trefoil protein has the ability to enhance corneal epithelial wound healing.    
     
     
       12. The method of  claim 8 , wherein said trefoil protein comprises a region having at least  90 %  sequence identity to residues  25 - 62  of the polypeptide set forth in SEQ ID NO:  4 , wherein said trefoil protein has the ability to enhance corneal epithelial wound healing.    
     
     
       13. The method of  claim 8 , wherein said disruption is a corneal ulcer, or is caused by a traumatic physical injury, eye surgery, a chemical exposure, or an ultraviolet light exposure.  
     
     
       14. The method of  claim 8 , wherein administration is topical.  
     
     
       15. A method for the treatment of a disruption of the corneal epithelium in a patient, said method comprising administering to the eye of said patient a trefoil protein comprising a region having at least  90 %  sequence identity, over more than  35  contiguous amino acid residues, to the polypeptide set forth in SEQ ID NO:  2  or  4 , wherein said trefoil protein has the ability to enhance corneal epithelial wound healing.    
     
     
       16. The method of  claim 15 , wherein said trefoil protein is the polypeptide set forth in SEQ ID NO:  2  or a biologically active fragment thereof comprising more than  35  contiguous amino acid residues of the polypeptide set forth in SEQ ID NO:  2 , wherein said trefoil protein has the ability to enhance corneal epithelial wound healing.  
     
     
       17. The method of  claim 15 , wherein said trefoil protein is the polypeptide set forth in SEQ ID NO:  4  or a biologically active fragment thereof comprising more than  35  contiguous amino acid residues of the polypeptide set forth in SEQ ID NO:  4 , wherein said trefoil protein has the ability to enhance corneal epithelial wound healing.  
     
     
       18. The method of  claim 15 , wherein said trefoil protein comprises a region having at least  90 %  sequence identity, over more than  35  contiguous amino acid residues, to the polypeptide set forth in SEQ ID NO:  2 , wherein said trefoil protein has the ability to enhance corneal epithelial wound healing.    
     
     
       19. The method of  claim 15 , wherein said trefoil protein comprises a region having at least  90 %  sequence identity, over more than  35  contiguous amino acid residues, to the polypeptide set forth in SEQ ID NO:  4 , wherein said trefoil protein has the ability to enhance corneal epithelial wound healing.    
     
     
       20. The method of  claim 15 , wherein said disruption is a corneal ulcer, or is caused by a traumatic physical injury, eye surgery, a chemical exposure, or an ultraviolet light exposure.  
     
     
       21. The method of  claim 15 , wherein administration is topical.

Join the waitlist — get patent alerts

Track USRE41028E — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.